

Cipla launches Mumbai's first Breathefree Lung Wellness Center, India's Most Advanced Integrated Lung Diagnostics Facility

Celebrating 90 years of healthcare innovation at Cipla, this Center also houses the first Sputum Inflammometry Lab in India

Mumbai, January 27, 2026: Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of its Breathefree Lung Wellness Center (BLWC) in Mumbai, India's most advanced integrated lung diagnostics and wellness center. This marks the company's second such facility, following New Delhi, and underscores Cipla's continued focus on expanding access to comprehensive respiratory diagnostics and care. The Mumbai BLWC is equipped with cutting-edge technology, globally benchmarked diagnostic protocols, and comprehensive Lung Health testing infrastructure aimed at making accurate, standardised, and accessible lung health assessments available to clinicians and patients in Mumbai and beyond.

Located in Mumbai's Prabhadevi, the Center has been designed to support diagnosis across a full spectrum of respiratory conditions – from Asthma and Chronic Obstructive Pulmonary Disease (COPD) to Interstitial Lung Diseases (ILDs) and other complex pulmonary disorders. It offers more than 60 specialised lung health assessments, covering pulmonary physiology, microbiology, immunology, blood chemistry, radiology, and advanced inflammation phenotyping. Key tests include spirometry, oscillometry, FeNO, F_nNO, DLCO, body plethysmography, cardiopulmonary exercise testing (CPET), X-ray and CT imaging, sleep studies, and a broad range of microbiology and immunology panels, delivered by highly trained technicians in line with global quality standards. Along with advanced diagnostic testing, BLWC brings patients access to rare and highly specialised services, including Pulmonary Rehabilitation, science-backed Pulmonary Nutrition, and comprehensive Smoking Cessation support, each designed to help individuals breathe easier, recover faster, and live healthier lives.

The Center also introduces India's first Sputum Inflammometry Lab. Integrated within a comprehensive lung diagnostics setup, it enables clinicians to better characterise airway inflammation in Asthma, COPD and other chronic respiratory diseases, supporting more precise diagnosis, improved disease monitoring, and optimised, personalised treatment pathways.

Commenting on this milestone, Achin Gupta, Managing Director and Global CEO Designate, Cipla Limited said, *"Respiratory care has been a cornerstone of Cipla's healthcare journey for decades. With the launch of our second Breathefree Lung Wellness Center, we are scaling an integrated model of respiratory diagnostics designed to serve patients in Mumbai and across the country. At a time when respiratory health is a growing concern, this Centre brings advanced and standardised diagnostics closer to*

clinicians and patients, enabling earlier detection, more precise care, and better long-term outcomes."

Dr. Jaideep Gogtay, Global Chief Medical Officer, Cipla Limited, added, *"The Breathefree Lung Wellness Centers represent a significant step forward in advancing how respiratory diseases are diagnosed and managed. By integrating comprehensive diagnostics with advanced capabilities such as Sputum Inflammometry, this Center enables a deeper understanding of airway inflammation and supports more precise and personalised therapy. The goal is to significantly strengthen long-term disease monitoring, reduce the likelihood of exacerbations, and meaningfully improve the quality of life for patients."*

Beyond diagnostics, the Breathefree Lung Wellness Center in Mumbai is envisioned as an important hub for training and research. It will equip clinicians and respiratory technicians with the latest diagnostic methodologies, serve as a platform for scientific collaboration among pulmonologists and respiratory researchers, and contribute to strengthening India's overall respiratory science ecosystem.

About Cipla

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec'25), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT Nov'25), and 3rd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Dec'25). For over nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#). To learn more about the diagnostics and wellness services offered at Breathefree Lung Wellness Center (BLWC), visit www.ciplablwc.com

Media Contacts:

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Diksha Maheshwari

E-Mail: Investor.Relations@cipla.com